CHRISTINA NICHOLSON: Open Payments
NPI 1528485471 · URBANDALE, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,437 in 193 payments from 19 companies in 2025. Trend: 2023 $562 · 2024 $626 · 2025 $3,437
Food & beverage: $3,437
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 21 | $471 |
| ABBVIE INC. | 31 | $460 |
| Teva Pharmaceuticals USA, Inc. | 15 | $382 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $381 |
| E.R. Squibb & Sons, L.L.C. | 11 | $182 |
| Neos Therapeutics, LP | 11 | $176 |
| Lundbeck LLC | 8 | $172 |
| MDD US Operations, LLC | 16 | $161 |
| Vanda Pharmaceuticals Inc. | 7 | $160 |
| Almatica Pharma LLC | 13 | $146 |
Products named: REXULTI, VRAYLAR, CAPLYTA, UZEDY, AUSTEDO XR, COBENFY, Qelbree, FANAPT.
Industry payments across IA — which companies pay providers there.
